Frontal lobe microglia, neurodegenerative protein accumulation, and cognitive function in people with HIV

Jacinta Murray1, Gregory Meloni1, Etty P Cortes2

  • 1Department of Neurology, The Icahn School of Medicine at Mount Sinai, Box 1137, Mount Sinai Medical Center, New York City, NY, 10029, USA.

Insights

Microglia activation (microgliosis) in HIV-infected individuals is linked to cognition but not amyloid or tau pathology. APOE ε4 status and sex influence inflammation around amyloid plaques.

Area of Science:

  • Neuroimmunology
  • Neuropathology
  • Neuroinflammation

Background:

  • Microglia play a role in Alzheimer's Disease (AD) pathogenesis.
  • Neuroinflammation is a key factor in AD development.
  • The interplay between microgliosis, amyloid-beta (Aβ) deposition, tau pathology, and cognition in the context of HIV infection is not fully understood.

Purpose of the Study:

  • To investigate the relationship between microgliosis, Aβ deposition, and phosphorylated tau (p-tau) in the neocortex of individuals with and without HIV.
  • To determine if microgliosis predicts cognitive function in a middle-aged cohort.
  • To examine the influence of HIV status, APOE ε4 allele, and sex on microgliosis and its association with neuropathology.

Main Methods:

  • Autopsy frontal lobe tissue from 191 individuals with detectable (HIV-D) and undetectable (HIV-U) HIV infection, and 63 controls were analyzed.
  • Immunohistochemistry (IHC) was used to assess Aβ plaques, neuronal p-tau, and microgliosis (Iba1, CD163, CD68).
  • Immunofluorescence (IF) quantified glia in the Aβ plaque microenvironment; cognitive correlations were evaluated.

Main Results:

  • No correlation was found between Aβ or p-tau accumulation and overall microgliosis severity.
  • Individuals with uncontrolled HIV exhibited the highest microgliosis but fewer Aβ plaques.
  • HIV status predicted microgliosis across large cortical regions, while APOE ε4 status and sex were dominant predictors of glial infiltrates within the Aβ plaque microenvironment.

Conclusions:

  • Microgliosis predicts cognition in HIV-D individuals, but not HIV-U.
  • Increased neuroinflammation does not initiate amyloid deposition in this cohort.
  • APOE ε4 status predicts increased plaque-associated inflammation once Aβ deposits are established.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
692
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
10.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
272